Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 523601, 7 pages
http://dx.doi.org/10.1155/2015/523601
Clinical Study

A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting

1Department of Hemato-Oncology, Chonnam National University Medical School, Gwangju 519-763, Republic of Korea
2Division of Clinical Pharmacology, Chonnam National University Hospital, Gwangju 519-763, Republic of Korea
3Department of Pharmacology, Chonnam National University Medical School, Gwangju 519-763, Republic of Korea
4Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju 519-763, Republic of Korea

Received 19 December 2014; Revised 21 January 2015; Accepted 3 February 2015

Academic Editor: Bernardo L. Rapoport

Copyright © 2015 Ka-Rham Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. C. Sun, D. C. Bodurka, C. B. Weaver et al., “Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer,” Supportive Care in Cancer, vol. 13, no. 4, pp. 219–227, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. F. M. Schnell, “Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control,” Oncologist, vol. 8, no. 2, pp. 187–198, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. P. J. Hesketh, “Chemotherapy-induced nausea and vomiting,” The New England Journal of Medicine, vol. 358, no. 23, pp. 2432–2494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Marty, P. Pouillart, S. Scholl et al., “Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis,” New England Journal of Medicine, vol. 322, no. 12, pp. 816–821, 1990. View at Publisher · View at Google Scholar · View at Scopus
  5. D. G. Warr, S. M. Grunberg, R. J. Gralla et al., “The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials,” European Journal of Cancer, vol. 41, no. 9, pp. 1278–1285, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. Network NCC, NCCN Clinical Practice Guidelines-Antiemesis. v. 1., 2014.
  7. J. Herrstedt, “Antiemetics an update and the MASCC guidelines applied in clinical practice,” Nature Clinical Practice Oncology, vol. 5, no. 1, pp. 32–43, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. P. J. Hesketh, M. G. Kris, S. M. Grunberg et al., “Proposal for classifying the acute emetogenicity of cancer chemotherapy,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 103–109, 1997. View at Google Scholar · View at Scopus
  9. Y. K. Kang, Y. H. Park, B. Y. Ryoo et al., “Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron,” Journal of International Medical Research, vol. 30, no. 3, pp. 220–229, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Mihara, K. Tojo, K. Uchimoto, S. Morita, and T. Goto, “Reevaluation of the effectiveness of ramosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis,” Anesthesia and Analgesia, vol. 117, no. 2, pp. 329–339, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. R. M. Navari, “Palonosetron for the treatment of chemotherapy-induced nausea and vomiting,” Expert Opinion on Pharmacotherapy, vol. 15, no. 17, pp. 2599–2608, 2014. View at Publisher · View at Google Scholar
  12. G. U. Roh, S. Y. Yang, J. K. Shim, and Y. L. Kwak, “Efficacy of palonosetron versus ramosetron on preventing opioid-based analgesia-related nausea and vomiting after lumbar spinal surgery: a prospective, randomized, and double-blind trial,” Spine, vol. 39, no. 9, pp. E543–E549, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Poli-Bigelli, J. Rodrigues-Pereira, A. D. Carides et al., “Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America,” Cancer, vol. 97, no. 12, pp. 3090–3098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Roila, M. Tonato, F. Cognetti et al., “Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone,” Journal of Clinical Oncology, vol. 9, no. 4, pp. 675–678, 1991. View at Google Scholar · View at Scopus
  15. V. A. Rhodes and R. W. McDaniel, “The Index of Nausea, Vomiting, and Retching: a new format of the lndex of Nausea and Vomiting,” Oncology Nursing Forum, vol. 26, no. 5, pp. 889–894, 1999. View at Google Scholar · View at Scopus
  16. R. de Wit, A. C. de Boer, G. H. M. Vd Linden, G. Stoter, A. Sparreboom, and J. Verweij, “Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy,” British Journal of Cancer, vol. 85, no. 8, pp. 1099–1101, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Roila, J. Herrstedt, M. Aapro et al., “Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference,” Annals of Oncology, vol. 21, supplement 5, pp. v232–v243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Sekine, Y. Segawa, K. Kubota, and T. Saeki, “Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis,” Cancer Science, vol. 104, no. 6, pp. 711–717, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Segawa, K. Aogi, K. Inoue et al., “A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy,” Annals of Oncology, vol. 20, no. 11, pp. 1874–1880, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Maemondo, N. Masuda, I. Sekine et al., “A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy,” Annals of Oncology, vol. 20, no. 11, pp. 1860–1866, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. O. Geling and H.-G. Eichler, “Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications,” Journal of Clinical Oncology, vol. 23, no. 6, pp. 1289–1294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. J. T. Hickok, J. A. Roscoe, G. R. Morrow et al., “5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial,” The Lancet Oncology, vol. 6, no. 10, pp. 765–772, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Ikari, K. Ogata, Y. Nakashima et al., “Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy,” Supportive Care in Cancer, vol. 22, no. 7, pp. 1959–1964, 2014. View at Publisher · View at Google Scholar · View at Scopus